Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry - PubMed
6 hours ago
- #Familial Hypercholesterolemia
- #Pediatric Cardiology
- #Lipid-Lowering Therapy
- Study focused on real-world management of familial hypercholesterolemia (FH) in pediatric patients over a 3-year follow-up from the LIPIGEN registry.
- 341 pediatric FH patients were analyzed, with 51.6% initiating lipid-lowering therapy (LLT) in the first year, increasing to 78.9% after 3 years.
- Statins were the most common treatment (43.9%), especially in children ≥8 years, followed by statin-ezetimibe combination (11.5%). Nutraceuticals were more common in younger children (<8 years).
- LLT led to a mean LDL-C reduction of 25.7%, with 50.2% reduction observed in patients on statin-ezetimibe combination therapy.
- Only 26.1% of patients achieved guideline-recommended LDL-C goals, with the highest success rates among those on combination therapy.
- The study highlights therapeutic inertia in pediatric FH management, emphasizing the need for earlier intervention and optimized treatment strategies to improve cardiovascular outcomes.